Pharma & Healthcare
Vaccine for Influenza- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
- Jul 14, 25
- ID: 374718
- Pages: 117
- Figures: 122
- Views: 8
The global market for Vaccine for Influenza was estimated to be worth US$ 8955 million in 2024 and is forecast to a readjusted size of US$ 12990 million by 2031 with a CAGR of 5.5% during the forecast period 2025-2031.
Global key players of Vaccine for Influenza include Sanofi, CSL and GSK, etc. The top five players hold a share about 75%. North America is the largest market, has a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Vaccine for Influenza, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Vaccine for Influenza by region & country, by Type, and by Application.
The Vaccine for Influenza market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccine for Influenza.
Market Segmentation
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
6 Months to 3 Years
> 3 Years
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Vaccine for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Vaccine for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Vaccine for Influenza in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Global key players of Vaccine for Influenza include Sanofi, CSL and GSK, etc. The top five players hold a share about 75%. North America is the largest market, has a share about 50%.
This report aims to provide a comprehensive presentation of the global market for Vaccine for Influenza, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Vaccine for Influenza by region & country, by Type, and by Application.
The Vaccine for Influenza market size, estimations, and forecasts are provided in terms of sales volume (M Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccine for Influenza.
Market Segmentation
By Company
Sanofi
CSL
GSK
Viatris
AstraZeneca
Hualan Bio
Changchun Institute of Biological
Sinovac
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
6 Months to 3 Years
> 3 Years
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Vaccine for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Vaccine for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Vaccine for Influenza in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Vaccine for Influenza Product Introduction
1.2 Global Vaccine for Influenza Market Size Forecast
1.2.1 Global Vaccine for Influenza Sales Value (2020-2031)
1.2.2 Global Vaccine for Influenza Sales Volume (2020-2031)
1.2.3 Global Vaccine for Influenza Sales Price (2020-2031)
1.3 Vaccine for Influenza Market Trends & Drivers
1.3.1 Vaccine for Influenza Industry Trends
1.3.2 Vaccine for Influenza Market Drivers & Opportunity
1.3.3 Vaccine for Influenza Market Challenges
1.3.4 Vaccine for Influenza Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Vaccine for Influenza Players Revenue Ranking (2024)
2.2 Global Vaccine for Influenza Revenue by Company (2020-2025)
2.3 Global Vaccine for Influenza Players Sales Volume Ranking (2024)
2.4 Global Vaccine for Influenza Sales Volume by Company Players (2020-2025)
2.5 Global Vaccine for Influenza Average Price by Company (2020-2025)
2.6 Key Manufacturers Vaccine for Influenza Manufacturing Base and Headquarters
2.7 Key Manufacturers Vaccine for Influenza Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Vaccine for Influenza
2.9 Vaccine for Influenza Market Competitive Analysis
2.9.1 Vaccine for Influenza Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Vaccine for Influenza Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Vaccine for Influenza Sales Value by Type
3.2.1 Global Vaccine for Influenza Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Vaccine for Influenza Sales Value, by Type (2020-2031)
3.2.3 Global Vaccine for Influenza Sales Value, by Type (%) (2020-2031)
3.3 Global Vaccine for Influenza Sales Volume by Type
3.3.1 Global Vaccine for Influenza Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Vaccine for Influenza Sales Volume, by Type (2020-2031)
3.3.3 Global Vaccine for Influenza Sales Volume, by Type (%) (2020-2031)
3.4 Global Vaccine for Influenza Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 6 Months to 3 Years
4.1.2 > 3 Years
4.2 Global Vaccine for Influenza Sales Value by Application
4.2.1 Global Vaccine for Influenza Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Vaccine for Influenza Sales Value, by Application (2020-2031)
4.2.3 Global Vaccine for Influenza Sales Value, by Application (%) (2020-2031)
4.3 Global Vaccine for Influenza Sales Volume by Application
4.3.1 Global Vaccine for Influenza Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Vaccine for Influenza Sales Volume, by Application (2020-2031)
4.3.3 Global Vaccine for Influenza Sales Volume, by Application (%) (2020-2031)
4.4 Global Vaccine for Influenza Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Vaccine for Influenza Sales Value by Region
5.1.1 Global Vaccine for Influenza Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Vaccine for Influenza Sales Value by Region (2020-2025)
5.1.3 Global Vaccine for Influenza Sales Value by Region (2026-2031)
5.1.4 Global Vaccine for Influenza Sales Value by Region (%), (2020-2031)
5.2 Global Vaccine for Influenza Sales Volume by Region
5.2.1 Global Vaccine for Influenza Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Vaccine for Influenza Sales Volume by Region (2020-2025)
5.2.3 Global Vaccine for Influenza Sales Volume by Region (2026-2031)
5.2.4 Global Vaccine for Influenza Sales Volume by Region (%), (2020-2031)
5.3 Global Vaccine for Influenza Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Vaccine for Influenza Sales Value, 2020-2031
5.4.2 North America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Vaccine for Influenza Sales Value, 2020-2031
5.5.2 Europe Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Vaccine for Influenza Sales Value, 2020-2031
5.6.2 Asia Pacific Vaccine for Influenza Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Vaccine for Influenza Sales Value, 2020-2031
5.7.2 South America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Vaccine for Influenza Sales Value, 2020-2031
5.8.2 Middle East & Africa Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Vaccine for Influenza Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Vaccine for Influenza Sales Value
6.2.1 Key Countries/Regions Vaccine for Influenza Sales Value, 2020-2031
6.2.2 Key Countries/Regions Vaccine for Influenza Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Vaccine for Influenza Sales Value, 2020-2031
6.3.2 United States Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Vaccine for Influenza Sales Value, 2020-2031
6.4.2 Europe Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Vaccine for Influenza Sales Value, 2020-2031
6.5.2 China Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.5.3 China Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Vaccine for Influenza Sales Value, 2020-2031
6.6.2 Japan Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Vaccine for Influenza Sales Value, 2020-2031
6.7.2 South Korea Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Vaccine for Influenza Sales Value, 2020-2031
6.8.2 Southeast Asia Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Vaccine for Influenza Sales Value, 2020-2031
6.9.2 India Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.9.3 India Vaccine for Influenza Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Company Information
7.1.2 Sanofi Introduction and Business Overview
7.1.3 Sanofi Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Sanofi Vaccine for Influenza Product Offerings
7.1.5 Sanofi Recent Development
7.2 CSL
7.2.1 CSL Company Information
7.2.2 CSL Introduction and Business Overview
7.2.3 CSL Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 CSL Vaccine for Influenza Product Offerings
7.2.5 CSL Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 GSK Vaccine for Influenza Product Offerings
7.3.5 GSK Recent Development
7.4 Viatris
7.4.1 Viatris Company Information
7.4.2 Viatris Introduction and Business Overview
7.4.3 Viatris Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Viatris Vaccine for Influenza Product Offerings
7.4.5 Viatris Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Company Information
7.5.2 AstraZeneca Introduction and Business Overview
7.5.3 AstraZeneca Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 AstraZeneca Vaccine for Influenza Product Offerings
7.5.5 AstraZeneca Recent Development
7.6 Hualan Bio
7.6.1 Hualan Bio Company Information
7.6.2 Hualan Bio Introduction and Business Overview
7.6.3 Hualan Bio Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Hualan Bio Vaccine for Influenza Product Offerings
7.6.5 Hualan Bio Recent Development
7.7 Changchun Institute of Biological
7.7.1 Changchun Institute of Biological Company Information
7.7.2 Changchun Institute of Biological Introduction and Business Overview
7.7.3 Changchun Institute of Biological Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Changchun Institute of Biological Vaccine for Influenza Product Offerings
7.7.5 Changchun Institute of Biological Recent Development
7.8 Sinovac
7.8.1 Sinovac Company Information
7.8.2 Sinovac Introduction and Business Overview
7.8.3 Sinovac Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sinovac Vaccine for Influenza Product Offerings
7.8.5 Sinovac Recent Development
7.9 BCHT
7.9.1 BCHT Company Information
7.9.2 BCHT Introduction and Business Overview
7.9.3 BCHT Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 BCHT Vaccine for Influenza Product Offerings
7.9.5 BCHT Recent Development
7.10 Jiangsu GDK
7.10.1 Jiangsu GDK Company Information
7.10.2 Jiangsu GDK Introduction and Business Overview
7.10.3 Jiangsu GDK Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Jiangsu GDK Vaccine for Influenza Product Offerings
7.10.5 Jiangsu GDK Recent Development
7.11 KM Biologics
7.11.1 KM Biologics Company Information
7.11.2 KM Biologics Introduction and Business Overview
7.11.3 KM Biologics Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 KM Biologics Vaccine for Influenza Product Offerings
7.11.5 KM Biologics Recent Development
8 Industry Chain Analysis
8.1 Vaccine for Influenza Industrial Chain
8.2 Vaccine for Influenza Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Vaccine for Influenza Sales Model
8.5.2 Sales Channel
8.5.3 Vaccine for Influenza Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
1.1 Vaccine for Influenza Product Introduction
1.2 Global Vaccine for Influenza Market Size Forecast
1.2.1 Global Vaccine for Influenza Sales Value (2020-2031)
1.2.2 Global Vaccine for Influenza Sales Volume (2020-2031)
1.2.3 Global Vaccine for Influenza Sales Price (2020-2031)
1.3 Vaccine for Influenza Market Trends & Drivers
1.3.1 Vaccine for Influenza Industry Trends
1.3.2 Vaccine for Influenza Market Drivers & Opportunity
1.3.3 Vaccine for Influenza Market Challenges
1.3.4 Vaccine for Influenza Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Vaccine for Influenza Players Revenue Ranking (2024)
2.2 Global Vaccine for Influenza Revenue by Company (2020-2025)
2.3 Global Vaccine for Influenza Players Sales Volume Ranking (2024)
2.4 Global Vaccine for Influenza Sales Volume by Company Players (2020-2025)
2.5 Global Vaccine for Influenza Average Price by Company (2020-2025)
2.6 Key Manufacturers Vaccine for Influenza Manufacturing Base and Headquarters
2.7 Key Manufacturers Vaccine for Influenza Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Vaccine for Influenza
2.9 Vaccine for Influenza Market Competitive Analysis
2.9.1 Vaccine for Influenza Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Vaccine for Influenza Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Trivalent Influenza Vaccine
3.1.2 Quadrivalent Influenza Vaccine
3.2 Global Vaccine for Influenza Sales Value by Type
3.2.1 Global Vaccine for Influenza Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Vaccine for Influenza Sales Value, by Type (2020-2031)
3.2.3 Global Vaccine for Influenza Sales Value, by Type (%) (2020-2031)
3.3 Global Vaccine for Influenza Sales Volume by Type
3.3.1 Global Vaccine for Influenza Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Vaccine for Influenza Sales Volume, by Type (2020-2031)
3.3.3 Global Vaccine for Influenza Sales Volume, by Type (%) (2020-2031)
3.4 Global Vaccine for Influenza Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 6 Months to 3 Years
4.1.2 > 3 Years
4.2 Global Vaccine for Influenza Sales Value by Application
4.2.1 Global Vaccine for Influenza Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Vaccine for Influenza Sales Value, by Application (2020-2031)
4.2.3 Global Vaccine for Influenza Sales Value, by Application (%) (2020-2031)
4.3 Global Vaccine for Influenza Sales Volume by Application
4.3.1 Global Vaccine for Influenza Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Vaccine for Influenza Sales Volume, by Application (2020-2031)
4.3.3 Global Vaccine for Influenza Sales Volume, by Application (%) (2020-2031)
4.4 Global Vaccine for Influenza Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Vaccine for Influenza Sales Value by Region
5.1.1 Global Vaccine for Influenza Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Vaccine for Influenza Sales Value by Region (2020-2025)
5.1.3 Global Vaccine for Influenza Sales Value by Region (2026-2031)
5.1.4 Global Vaccine for Influenza Sales Value by Region (%), (2020-2031)
5.2 Global Vaccine for Influenza Sales Volume by Region
5.2.1 Global Vaccine for Influenza Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Vaccine for Influenza Sales Volume by Region (2020-2025)
5.2.3 Global Vaccine for Influenza Sales Volume by Region (2026-2031)
5.2.4 Global Vaccine for Influenza Sales Volume by Region (%), (2020-2031)
5.3 Global Vaccine for Influenza Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Vaccine for Influenza Sales Value, 2020-2031
5.4.2 North America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Vaccine for Influenza Sales Value, 2020-2031
5.5.2 Europe Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Vaccine for Influenza Sales Value, 2020-2031
5.6.2 Asia Pacific Vaccine for Influenza Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Vaccine for Influenza Sales Value, 2020-2031
5.7.2 South America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Vaccine for Influenza Sales Value, 2020-2031
5.8.2 Middle East & Africa Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Vaccine for Influenza Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Vaccine for Influenza Sales Value
6.2.1 Key Countries/Regions Vaccine for Influenza Sales Value, 2020-2031
6.2.2 Key Countries/Regions Vaccine for Influenza Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Vaccine for Influenza Sales Value, 2020-2031
6.3.2 United States Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Vaccine for Influenza Sales Value, 2020-2031
6.4.2 Europe Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Vaccine for Influenza Sales Value, 2020-2031
6.5.2 China Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.5.3 China Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Vaccine for Influenza Sales Value, 2020-2031
6.6.2 Japan Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Vaccine for Influenza Sales Value, 2020-2031
6.7.2 South Korea Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Vaccine for Influenza Sales Value, 2020-2031
6.8.2 Southeast Asia Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Vaccine for Influenza Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Vaccine for Influenza Sales Value, 2020-2031
6.9.2 India Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
6.9.3 India Vaccine for Influenza Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Company Information
7.1.2 Sanofi Introduction and Business Overview
7.1.3 Sanofi Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Sanofi Vaccine for Influenza Product Offerings
7.1.5 Sanofi Recent Development
7.2 CSL
7.2.1 CSL Company Information
7.2.2 CSL Introduction and Business Overview
7.2.3 CSL Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 CSL Vaccine for Influenza Product Offerings
7.2.5 CSL Recent Development
7.3 GSK
7.3.1 GSK Company Information
7.3.2 GSK Introduction and Business Overview
7.3.3 GSK Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 GSK Vaccine for Influenza Product Offerings
7.3.5 GSK Recent Development
7.4 Viatris
7.4.1 Viatris Company Information
7.4.2 Viatris Introduction and Business Overview
7.4.3 Viatris Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Viatris Vaccine for Influenza Product Offerings
7.4.5 Viatris Recent Development
7.5 AstraZeneca
7.5.1 AstraZeneca Company Information
7.5.2 AstraZeneca Introduction and Business Overview
7.5.3 AstraZeneca Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 AstraZeneca Vaccine for Influenza Product Offerings
7.5.5 AstraZeneca Recent Development
7.6 Hualan Bio
7.6.1 Hualan Bio Company Information
7.6.2 Hualan Bio Introduction and Business Overview
7.6.3 Hualan Bio Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Hualan Bio Vaccine for Influenza Product Offerings
7.6.5 Hualan Bio Recent Development
7.7 Changchun Institute of Biological
7.7.1 Changchun Institute of Biological Company Information
7.7.2 Changchun Institute of Biological Introduction and Business Overview
7.7.3 Changchun Institute of Biological Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Changchun Institute of Biological Vaccine for Influenza Product Offerings
7.7.5 Changchun Institute of Biological Recent Development
7.8 Sinovac
7.8.1 Sinovac Company Information
7.8.2 Sinovac Introduction and Business Overview
7.8.3 Sinovac Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Sinovac Vaccine for Influenza Product Offerings
7.8.5 Sinovac Recent Development
7.9 BCHT
7.9.1 BCHT Company Information
7.9.2 BCHT Introduction and Business Overview
7.9.3 BCHT Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 BCHT Vaccine for Influenza Product Offerings
7.9.5 BCHT Recent Development
7.10 Jiangsu GDK
7.10.1 Jiangsu GDK Company Information
7.10.2 Jiangsu GDK Introduction and Business Overview
7.10.3 Jiangsu GDK Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Jiangsu GDK Vaccine for Influenza Product Offerings
7.10.5 Jiangsu GDK Recent Development
7.11 KM Biologics
7.11.1 KM Biologics Company Information
7.11.2 KM Biologics Introduction and Business Overview
7.11.3 KM Biologics Vaccine for Influenza Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 KM Biologics Vaccine for Influenza Product Offerings
7.11.5 KM Biologics Recent Development
8 Industry Chain Analysis
8.1 Vaccine for Influenza Industrial Chain
8.2 Vaccine for Influenza Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Vaccine for Influenza Sales Model
8.5.2 Sales Channel
8.5.3 Vaccine for Influenza Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Vaccine for Influenza Market Trends
Table 2. Vaccine for Influenza Market Drivers & Opportunity
Table 3. Vaccine for Influenza Market Challenges
Table 4. Vaccine for Influenza Market Restraints
Table 5. Global Vaccine for Influenza Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Vaccine for Influenza Revenue Market Share by Company (2020-2025)
Table 7. Global Vaccine for Influenza Sales Volume by Company (2020-2025) & (M Units)
Table 8. Global Vaccine for Influenza Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Vaccine for Influenza Price by Company (2020-2025) & (US$/Unit)
Table 10. Key Manufacturers Vaccine for Influenza Manufacturing Base and Headquarters
Table 11. Key Manufacturers Vaccine for Influenza Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Vaccine for Influenza
Table 13. Global Vaccine for Influenza Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Vaccine for Influenza Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Vaccine for Influenza Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Vaccine for Influenza Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Vaccine for Influenza Sales Market Share in Value by Type (2020-2025)
Table 20. Global Vaccine for Influenza Sales Market Share in Value by Type (2026-2031)
Table 21. Global Vaccine for Influenza Sales Volume by Type: 2020 VS 2024 VS 2031 (M Units)
Table 22. Global Vaccine for Influenza Sales Volume by Type (2020-2025) & (M Units)
Table 23. Global Vaccine for Influenza Sales Volume by Type (2026-2031) & (M Units)
Table 24. Global Vaccine for Influenza Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Vaccine for Influenza Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Vaccine for Influenza Price by Type (2020-2025) & (US$/Unit)
Table 27. Global Vaccine for Influenza Price by Type (2026-2031) & (US$/Unit)
Table 28. Global Vaccine for Influenza Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Vaccine for Influenza Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Vaccine for Influenza Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Vaccine for Influenza Sales Market Share in Value by Application (2020-2025)
Table 32. Global Vaccine for Influenza Sales Market Share in Value by Application (2026-2031)
Table 33. Global Vaccine for Influenza Sales Volume by Application: 2020 VS 2024 VS 2031 (M Units)
Table 34. Global Vaccine for Influenza Sales Volume by Application (2020-2025) & (M Units)
Table 35. Global Vaccine for Influenza Sales Volume by Application (2026-2031) & (M Units)
Table 36. Global Vaccine for Influenza Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Vaccine for Influenza Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Vaccine for Influenza Price by Application (2020-2025) & (US$/Unit)
Table 39. Global Vaccine for Influenza Price by Application (2026-2031) & (US$/Unit)
Table 40. Global Vaccine for Influenza Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Vaccine for Influenza Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Vaccine for Influenza Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Vaccine for Influenza Sales Value by Region (2020-2025) & (%)
Table 44. Global Vaccine for Influenza Sales Value by Region (2026-2031) & (%)
Table 45. Global Vaccine for Influenza Sales Volume by Region (M Units): 2020 VS 2024 VS 2031
Table 46. Global Vaccine for Influenza Sales Volume by Region (2020-2025) & (M Units)
Table 47. Global Vaccine for Influenza Sales Volume by Region (2026-2031) & (M Units)
Table 48. Global Vaccine for Influenza Sales Volume by Region (2020-2025) & (%)
Table 49. Global Vaccine for Influenza Sales Volume by Region (2026-2031) & (%)
Table 50. Global Vaccine for Influenza Average Price by Region (2020-2025) & (US$/Unit)
Table 51. Global Vaccine for Influenza Average Price by Region (2026-2031) & (US$/Unit)
Table 52. Key Countries/Regions Vaccine for Influenza Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Vaccine for Influenza Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Vaccine for Influenza Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Vaccine for Influenza Sales Volume, (2020-2025) & (M Units)
Table 56. Key Countries/Regions Vaccine for Influenza Sales Volume, (2026-2031) & (M Units)
Table 57. Sanofi Company Information
Table 58. Sanofi Introduction and Business Overview
Table 59. Sanofi Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 60. Sanofi Vaccine for Influenza Product Offerings
Table 61. Sanofi Recent Development
Table 62. CSL Company Information
Table 63. CSL Introduction and Business Overview
Table 64. CSL Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. CSL Vaccine for Influenza Product Offerings
Table 66. CSL Recent Development
Table 67. GSK Company Information
Table 68. GSK Introduction and Business Overview
Table 69. GSK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. GSK Vaccine for Influenza Product Offerings
Table 71. GSK Recent Development
Table 72. Viatris Company Information
Table 73. Viatris Introduction and Business Overview
Table 74. Viatris Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Viatris Vaccine for Influenza Product Offerings
Table 76. Viatris Recent Development
Table 77. AstraZeneca Company Information
Table 78. AstraZeneca Introduction and Business Overview
Table 79. AstraZeneca Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. AstraZeneca Vaccine for Influenza Product Offerings
Table 81. AstraZeneca Recent Development
Table 82. Hualan Bio Company Information
Table 83. Hualan Bio Introduction and Business Overview
Table 84. Hualan Bio Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Hualan Bio Vaccine for Influenza Product Offerings
Table 86. Hualan Bio Recent Development
Table 87. Changchun Institute of Biological Company Information
Table 88. Changchun Institute of Biological Introduction and Business Overview
Table 89. Changchun Institute of Biological Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Changchun Institute of Biological Vaccine for Influenza Product Offerings
Table 91. Changchun Institute of Biological Recent Development
Table 92. Sinovac Company Information
Table 93. Sinovac Introduction and Business Overview
Table 94. Sinovac Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Sinovac Vaccine for Influenza Product Offerings
Table 96. Sinovac Recent Development
Table 97. BCHT Company Information
Table 98. BCHT Introduction and Business Overview
Table 99. BCHT Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. BCHT Vaccine for Influenza Product Offerings
Table 101. BCHT Recent Development
Table 102. Jiangsu GDK Company Information
Table 103. Jiangsu GDK Introduction and Business Overview
Table 104. Jiangsu GDK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Jiangsu GDK Vaccine for Influenza Product Offerings
Table 106. Jiangsu GDK Recent Development
Table 107. KM Biologics Company Information
Table 108. KM Biologics Introduction and Business Overview
Table 109. KM Biologics Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. KM Biologics Vaccine for Influenza Product Offerings
Table 111. KM Biologics Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. Vaccine for Influenza Downstream Customers
Table 115. Vaccine for Influenza Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine for Influenza Product Picture
Figure 2. Global Vaccine for Influenza Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Vaccine for Influenza Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Vaccine for Influenza Sales Volume (2020-2031) & (M Units)
Figure 5. Global Vaccine for Influenza Sales Price (2020-2031) & (US$/Unit)
Figure 6. Vaccine for Influenza Report Years Considered
Figure 7. Global Vaccine for Influenza Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Vaccine for Influenza Players Sales Volume Ranking (2024) & (M Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine for Influenza Revenue in 2024
Figure 10. Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Trivalent Influenza Vaccine Picture
Figure 12. Quadrivalent Influenza Vaccine Picture
Figure 13. Global Vaccine for Influenza Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global Vaccine for Influenza Sales Value Market Share by Type, 2024 & 2031
Figure 15. Global Vaccine for Influenza Sales Volume by Type (2020 VS 2024 VS 2031) & (M Units)
Figure 16. Global Vaccine for Influenza Sales Volume Market Share by Type, 2024 & 2031
Figure 17. Global Vaccine for Influenza Price by Type (2020-2031) & (US$/Unit)
Figure 18. Product Picture of 6 Months to 3 Years
Figure 19. Product Picture of > 3 Years
Figure 20. Global Vaccine for Influenza Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 21. Global Vaccine for Influenza Sales Value Market Share by Application, 2024 & 2031
Figure 22. Global Vaccine for Influenza Sales Volume by Application (2020 VS 2024 VS 2031) & (M Units)
Figure 23. Global Vaccine for Influenza Sales Volume Market Share by Application, 2024 & 2031
Figure 24. Global Vaccine for Influenza Price by Application (2020-2031) & (US$/Unit)
Figure 25. North America Vaccine for Influenza Sales Value (2020-2031) & (US$ Million)
Figure 26. North America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 27. Europe Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 28. Europe Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 29. Asia Pacific Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 30. Asia Pacific Vaccine for Influenza Sales Value by Region (%), 2024 VS 2031
Figure 31. South America Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 32. South America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 33. Middle East & Africa Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 34. Middle East & Africa Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 35. Key Countries/Regions Vaccine for Influenza Sales Value (%), (2020-2031)
Figure 36. Key Countries/Regions Vaccine for Influenza Sales Volume (%), (2020-2031)
Figure 37. United States Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 38. United States Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 39. United States Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 40. Europe Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 41. Europe Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 42. Europe Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 43. China Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 44. China Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 45. China Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 46. Japan Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 47. Japan Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 48. Japan Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 49. South Korea Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 50. South Korea Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 51. South Korea Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 52. Southeast Asia Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 53. Southeast Asia Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 54. Southeast Asia Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 55. India Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 56. India Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 57. India Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 58. Vaccine for Influenza Industrial Chain
Figure 59. Vaccine for Influenza Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Vaccine for Influenza Market Trends
Table 2. Vaccine for Influenza Market Drivers & Opportunity
Table 3. Vaccine for Influenza Market Challenges
Table 4. Vaccine for Influenza Market Restraints
Table 5. Global Vaccine for Influenza Revenue by Company (2020-2025) & (US$ Million)
Table 6. Global Vaccine for Influenza Revenue Market Share by Company (2020-2025)
Table 7. Global Vaccine for Influenza Sales Volume by Company (2020-2025) & (M Units)
Table 8. Global Vaccine for Influenza Sales Volume Market Share by Company (2020-2025)
Table 9. Global Market Vaccine for Influenza Price by Company (2020-2025) & (US$/Unit)
Table 10. Key Manufacturers Vaccine for Influenza Manufacturing Base and Headquarters
Table 11. Key Manufacturers Vaccine for Influenza Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Vaccine for Influenza
Table 13. Global Vaccine for Influenza Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccine for Influenza as of 2024)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Vaccine for Influenza Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
Table 17. Global Vaccine for Influenza Sales Value by Type (2020-2025) & (US$ Million)
Table 18. Global Vaccine for Influenza Sales Value by Type (2026-2031) & (US$ Million)
Table 19. Global Vaccine for Influenza Sales Market Share in Value by Type (2020-2025)
Table 20. Global Vaccine for Influenza Sales Market Share in Value by Type (2026-2031)
Table 21. Global Vaccine for Influenza Sales Volume by Type: 2020 VS 2024 VS 2031 (M Units)
Table 22. Global Vaccine for Influenza Sales Volume by Type (2020-2025) & (M Units)
Table 23. Global Vaccine for Influenza Sales Volume by Type (2026-2031) & (M Units)
Table 24. Global Vaccine for Influenza Sales Market Share in Volume by Type (2020-2025)
Table 25. Global Vaccine for Influenza Sales Market Share in Volume by Type (2026-2031)
Table 26. Global Vaccine for Influenza Price by Type (2020-2025) & (US$/Unit)
Table 27. Global Vaccine for Influenza Price by Type (2026-2031) & (US$/Unit)
Table 28. Global Vaccine for Influenza Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
Table 29. Global Vaccine for Influenza Sales Value by Application (2020-2025) & (US$ Million)
Table 30. Global Vaccine for Influenza Sales Value by Application (2026-2031) & (US$ Million)
Table 31. Global Vaccine for Influenza Sales Market Share in Value by Application (2020-2025)
Table 32. Global Vaccine for Influenza Sales Market Share in Value by Application (2026-2031)
Table 33. Global Vaccine for Influenza Sales Volume by Application: 2020 VS 2024 VS 2031 (M Units)
Table 34. Global Vaccine for Influenza Sales Volume by Application (2020-2025) & (M Units)
Table 35. Global Vaccine for Influenza Sales Volume by Application (2026-2031) & (M Units)
Table 36. Global Vaccine for Influenza Sales Market Share in Volume by Application (2020-2025)
Table 37. Global Vaccine for Influenza Sales Market Share in Volume by Application (2026-2031)
Table 38. Global Vaccine for Influenza Price by Application (2020-2025) & (US$/Unit)
Table 39. Global Vaccine for Influenza Price by Application (2026-2031) & (US$/Unit)
Table 40. Global Vaccine for Influenza Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
Table 41. Global Vaccine for Influenza Sales Value by Region (2020-2025) & (US$ Million)
Table 42. Global Vaccine for Influenza Sales Value by Region (2026-2031) & (US$ Million)
Table 43. Global Vaccine for Influenza Sales Value by Region (2020-2025) & (%)
Table 44. Global Vaccine for Influenza Sales Value by Region (2026-2031) & (%)
Table 45. Global Vaccine for Influenza Sales Volume by Region (M Units): 2020 VS 2024 VS 2031
Table 46. Global Vaccine for Influenza Sales Volume by Region (2020-2025) & (M Units)
Table 47. Global Vaccine for Influenza Sales Volume by Region (2026-2031) & (M Units)
Table 48. Global Vaccine for Influenza Sales Volume by Region (2020-2025) & (%)
Table 49. Global Vaccine for Influenza Sales Volume by Region (2026-2031) & (%)
Table 50. Global Vaccine for Influenza Average Price by Region (2020-2025) & (US$/Unit)
Table 51. Global Vaccine for Influenza Average Price by Region (2026-2031) & (US$/Unit)
Table 52. Key Countries/Regions Vaccine for Influenza Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
Table 53. Key Countries/Regions Vaccine for Influenza Sales Value, (2020-2025) & (US$ Million)
Table 54. Key Countries/Regions Vaccine for Influenza Sales Value, (2026-2031) & (US$ Million)
Table 55. Key Countries/Regions Vaccine for Influenza Sales Volume, (2020-2025) & (M Units)
Table 56. Key Countries/Regions Vaccine for Influenza Sales Volume, (2026-2031) & (M Units)
Table 57. Sanofi Company Information
Table 58. Sanofi Introduction and Business Overview
Table 59. Sanofi Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 60. Sanofi Vaccine for Influenza Product Offerings
Table 61. Sanofi Recent Development
Table 62. CSL Company Information
Table 63. CSL Introduction and Business Overview
Table 64. CSL Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 65. CSL Vaccine for Influenza Product Offerings
Table 66. CSL Recent Development
Table 67. GSK Company Information
Table 68. GSK Introduction and Business Overview
Table 69. GSK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 70. GSK Vaccine for Influenza Product Offerings
Table 71. GSK Recent Development
Table 72. Viatris Company Information
Table 73. Viatris Introduction and Business Overview
Table 74. Viatris Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 75. Viatris Vaccine for Influenza Product Offerings
Table 76. Viatris Recent Development
Table 77. AstraZeneca Company Information
Table 78. AstraZeneca Introduction and Business Overview
Table 79. AstraZeneca Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. AstraZeneca Vaccine for Influenza Product Offerings
Table 81. AstraZeneca Recent Development
Table 82. Hualan Bio Company Information
Table 83. Hualan Bio Introduction and Business Overview
Table 84. Hualan Bio Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 85. Hualan Bio Vaccine for Influenza Product Offerings
Table 86. Hualan Bio Recent Development
Table 87. Changchun Institute of Biological Company Information
Table 88. Changchun Institute of Biological Introduction and Business Overview
Table 89. Changchun Institute of Biological Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Changchun Institute of Biological Vaccine for Influenza Product Offerings
Table 91. Changchun Institute of Biological Recent Development
Table 92. Sinovac Company Information
Table 93. Sinovac Introduction and Business Overview
Table 94. Sinovac Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 95. Sinovac Vaccine for Influenza Product Offerings
Table 96. Sinovac Recent Development
Table 97. BCHT Company Information
Table 98. BCHT Introduction and Business Overview
Table 99. BCHT Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 100. BCHT Vaccine for Influenza Product Offerings
Table 101. BCHT Recent Development
Table 102. Jiangsu GDK Company Information
Table 103. Jiangsu GDK Introduction and Business Overview
Table 104. Jiangsu GDK Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 105. Jiangsu GDK Vaccine for Influenza Product Offerings
Table 106. Jiangsu GDK Recent Development
Table 107. KM Biologics Company Information
Table 108. KM Biologics Introduction and Business Overview
Table 109. KM Biologics Vaccine for Influenza Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 110. KM Biologics Vaccine for Influenza Product Offerings
Table 111. KM Biologics Recent Development
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. Vaccine for Influenza Downstream Customers
Table 115. Vaccine for Influenza Distributors List
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine for Influenza Product Picture
Figure 2. Global Vaccine for Influenza Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Global Vaccine for Influenza Sales Value (2020-2031) & (US$ Million)
Figure 4. Global Vaccine for Influenza Sales Volume (2020-2031) & (M Units)
Figure 5. Global Vaccine for Influenza Sales Price (2020-2031) & (US$/Unit)
Figure 6. Vaccine for Influenza Report Years Considered
Figure 7. Global Vaccine for Influenza Players Revenue Ranking (2024) & (US$ Million)
Figure 8. Global Vaccine for Influenza Players Sales Volume Ranking (2024) & (M Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine for Influenza Revenue in 2024
Figure 10. Vaccine for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 11. Trivalent Influenza Vaccine Picture
Figure 12. Quadrivalent Influenza Vaccine Picture
Figure 13. Global Vaccine for Influenza Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
Figure 14. Global Vaccine for Influenza Sales Value Market Share by Type, 2024 & 2031
Figure 15. Global Vaccine for Influenza Sales Volume by Type (2020 VS 2024 VS 2031) & (M Units)
Figure 16. Global Vaccine for Influenza Sales Volume Market Share by Type, 2024 & 2031
Figure 17. Global Vaccine for Influenza Price by Type (2020-2031) & (US$/Unit)
Figure 18. Product Picture of 6 Months to 3 Years
Figure 19. Product Picture of > 3 Years
Figure 20. Global Vaccine for Influenza Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
Figure 21. Global Vaccine for Influenza Sales Value Market Share by Application, 2024 & 2031
Figure 22. Global Vaccine for Influenza Sales Volume by Application (2020 VS 2024 VS 2031) & (M Units)
Figure 23. Global Vaccine for Influenza Sales Volume Market Share by Application, 2024 & 2031
Figure 24. Global Vaccine for Influenza Price by Application (2020-2031) & (US$/Unit)
Figure 25. North America Vaccine for Influenza Sales Value (2020-2031) & (US$ Million)
Figure 26. North America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 27. Europe Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 28. Europe Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 29. Asia Pacific Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 30. Asia Pacific Vaccine for Influenza Sales Value by Region (%), 2024 VS 2031
Figure 31. South America Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 32. South America Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 33. Middle East & Africa Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 34. Middle East & Africa Vaccine for Influenza Sales Value by Country (%), 2024 VS 2031
Figure 35. Key Countries/Regions Vaccine for Influenza Sales Value (%), (2020-2031)
Figure 36. Key Countries/Regions Vaccine for Influenza Sales Volume (%), (2020-2031)
Figure 37. United States Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 38. United States Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 39. United States Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 40. Europe Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 41. Europe Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 42. Europe Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 43. China Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 44. China Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 45. China Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 46. Japan Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 47. Japan Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 48. Japan Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 49. South Korea Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 50. South Korea Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 51. South Korea Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 52. Southeast Asia Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 53. Southeast Asia Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 54. Southeast Asia Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 55. India Vaccine for Influenza Sales Value, (2020-2031) & (US$ Million)
Figure 56. India Vaccine for Influenza Sales Value by Type (%), 2024 VS 2031
Figure 57. India Vaccine for Influenza Sales Value by Application (%), 2024 VS 2031
Figure 58. Vaccine for Influenza Industrial Chain
Figure 59. Vaccine for Influenza Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global White Oil Market Research Report 2025
Aug 11, 25
Global Piezo Materials Market Research Report 2025
Aug 11, 25
Global Piezoceramic Materials Market Research Report 2025
Aug 11, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232